Primary manuscript
Preview
Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial
Reid HM, Maginn M, Perkins CM, Mulvaney EP, Boyce M, Yamamoto T, Kinsella BT.
Front Pharmacol
21 December 2023
Review
Preview
Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges
Mundy C, Bush J, Cheriyan J, Lorch U, Stringer S, Taubel J, Wydenbach K, Hardman TC.
Front Pharmacol
02 November 2023
Review
Preview
The future of clinical trials and drug development: 2050
Hardman TC, Aitchison R, Scaife R, Edwards J, Slater G.
Drugs Context
14 June 2023
Primary manuscript
Preview
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control
Zeng X, Qing J, Li CM, Lu J, Yamawaki T, Hsu YH, Vander Lugt B, Hsu H, Busby J, McDowell PJ, Jackson DJ, Djukanovic R, Matthews JG, Arron JR, Bradding P, Brightling CE, Chaudhuri R, Choy DF, Cowan D, Fowler SJ, Hardman TC, Harrison T, Howarth P, Lordan J, Mansur AH, Menzies-Gow A, Pavord ID, Walker S, Woodcock A, Heaney LG; investigators for the UK MRC Refractory Asthma Stratification Program (RASP-UK).
J Allergy Clin Immunol
14 June 2023
Primary manuscript
Preview
Multidisciplinary paper on patient blood management in cardiothoracic surgery in the UK: perspectives on practice during COVID-19
Al-Attar N, Gaer J, Giordano V, Harris E, Kirk A, Loubani M, Meybohm P, Sayeed R, Stock U, Travers J, Whiteman B.
J Cardiothorac Surg
03 April 2023
Primary manuscript
Preview
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
Taylor PC, Askari A, Choy E, Ehrenstein MR, Else S, Nisar MK.
BMC Med
14 February 2023
Primary manuscript
Preview
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex
Eastwood MC, Busby J, Jackson DJ, Pavord ID, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan D, Mansur AH, Fowler SJ, Howarth P, Lordan J, Menzies-Gow A, Harrison T, Robinson DS, Holweg CTJ, Matthews JG, Heaney LG; Refractory Asthma Stratification Programme (UK) Investigators.
J Allergy Clin Immunol Pract
09 January 2023
Primary manuscript
Preview
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine
Kompier R, Neels P, Beyer W, Hardman T, Lioznov D, Kharit S, Kostinov M.
F1000Res
17 November 2022
Primary manuscript
Preview
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators.
Kidney Int
21 October 2022
Primary manuscript
Preview
Changes to working practices in medical communications during the COVID-19 pandemic: Insights from two surveys.
Hardman TC, Lee C, Llewellyn P, Walker S
Medical Writing
10 September 2022
Primary manuscript
Preview
Lipidome Analysis in Brain and Peripheral Plasma Following Milk Fat Globule Membrane Supplementation in Rodents
Davies R, van Diepen JA, Brink LR, Bijlsma S, Neufeld KM, Cryan JF, O'Mahony SM, Bobeldijk I, Gross G.
Mol Nutr Food Res
06 September 2022
Review
Preview
Aromatic ointments for the common cold: what does the science say?
Smith A, Matthews O.
Drugs Context
17 August 2022
Primary manuscript
Preview
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation
Diver S, Haldar K, McDowell PJ, Busby J, Mistry V, Micieli C, Brown V, Cox C, Yang F, Borg C, Shrimanker R, Ramsheh MY, Hardman T, Arron J, Bradding P, Cowan D, Mansur AH, Fowler SJ, Lordan J, Menzies-Gow A, Robinson D, Matthews J, Pavord ID, Chaudhuri R, Heaney LG, Barer MR, Brightling C; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
Allergy
01 July 2022
Primary manuscript
Preview
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes
McDowell PJ, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan D, Mansur AH, Fowler SJ, Diver SE, Howarth P, Lordan J, Menzies-Gow A, Harrison T, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, Heaney LG.
Am J Respir Crit Care Med
13 May 2022
Primary manuscript
Preview
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
Ariceta G, Collard L, Abroug S, Moochhala SH, Gould E, Boussetta A, Ben Hmida M, De S, Hunley TE, Jarraya F, Fraga G, Banos A, Lindner E, Dehmel B, Schalk G.
Pediatr Nephrol
14 April 2022
Primary manuscript
Preview
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
Efimov SV, Matsiyeuskaya NV, Boytsova OV, Akhieva LY, Kuntsevich EV, Troshina AA, Kvasova EI, Tikhonov AA, Khomyakova NF, Harrison F, Rossi JF, Hardman TC.
Drugs Context
21 March 2022
Review
Preview
Azoximer Bromide: Mystery, Serendipity, and Promise
Grivtsova LY, Falaleeva NA, Tupitsyn NN.
Front Oncol
27 September 2021
Primary manuscript
Preview
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Busby J, Matthews JG, Chaudhuri R, Pavord ID, Hardman TC, Arron JR, Bradding P, Brightling CE, Choy DF, Cowan DC, Djukanovic R, Hanratty CE, Harrison TW, Holweg CT, Howarth PH, Fowler SJ, Lordan JL, Mansur AH, Menzies-Gow A, Niven RM, Robinson DS, Walker SM, Woodcock A, Heaney LG; investigators for the MRC Refractory Asthma Stratification Programme.
Eur Respir J
25 September 2021
Primary manuscript
Preview
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
Efimov SV, Matsiyeuskaya NV, Boytsova OV, Akhieva LY, Kvasova EI, Harrison F, Karpova YS, Tikhonov A, Khomyakova NF, Hardman T, Rossi JF.
Drugs Context
08 April 2021
Primary manuscript
Preview
Challenges of working from home during the COVID-19 pandemic: A survey to inform working practices. Medical Writing
Hardman TC, Llewellyn P, Walker S
Medical Writing
18 March 2021
Primary manuscript
Preview
A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts
Gomez-Cabrero D, Walter S, Abugessaisa I, Miñambres-Herraiz R, Palomares LB, Butcher L, Erusalimsky JD, Garcia-Garcia FJ, Carnicero J, Hardman TC, Mischak H, Zürbig P, Hackl M, Grillari J, Fiorillo E, Cucca F, Cesari M, Carrie I, Colpo M, Bandinelli S, Feart C, Peres K, Dartigues JF, Helmer C, Viña J, Olaso G, GarcÃa-Palmero I, MartÃnez JG, Jansen-Dürr P, Grune T, Weber D, Lippi G, Bonaguri C, Sinclair AJ, Tegner J, Rodriguez-Mañas L; FRAILOMIC initiative.
Geroscience
18 February 2021
Review
Preview
How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum
Rengelshausen J, Breithaupt-Groegler K, Donath F, Erb-Zohar K, Hardman T, Mikus G, Plassmann S, Wensing G, Sourgens H.
Ther Innov Regul Sci
03 February 2021
Primary manuscript
Preview
Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies
Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E.
Pediatr Nephrol
30 January 2021
Review
Preview
Human challenge trials the covid-19 vaccines still have much to teach us Response
Cheriyan J, Cromie A, Hammond M, Hardman TC, Lorch U, Taubel J on behalf of the Association of Human Pharmacology in the Pharmaceutical Industry
08 January 2021
Poster
Preview
Disease Severity Impact on Long-Term Virologic Response to Ibalizumab In Expanded Access Protocol (Tmb-311)
P. Kumar, J. Leider, J. Slim, G. Moyle, M. Leonard, R.B. Cash, S. Weinheimer, P. Mesquita.
Open Forum Infectious Diseases
31 December 2020
Primary manuscript
Preview
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease
Nar H, Schnapp G, Hucke O, Hardman TC, Klein T.
ChemMedChem
21 December 2020
Primary manuscript
Preview
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
H. Jullien, M. Leonard, R.B. Cash, P. Mesquita, S. Weinheimer, C. Marsolais
Rev Antiviral Ther Infect Dis
07 December 2020
Review
Preview
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges
Khan S, Albayaty M, Bush J, Cheriyan J, Cromie A, Koch A, Hammond M, Mair S, Lorch U, Stringer S, Taubel J, Hardman TC.
Front Pharmacol
19 November 2020
Primary manuscript
Preview
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA; Inhaled Interferon Beta COVID-19 Study Group.
Lancet Respir Med
15 November 2020
Review
Preview
Impact of the COVID-19 Pandemic on Clinical Trial Conduct: Lessons for the Future.
Harrison F
f1000Research
30 September 2020
Primary manuscript
Preview
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Mansur AH, Fowler SJ, Niven RM, Howarth PH, Lordan JL, Menzies-Gow A, Harrison TW, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID; investigators for the MRC Refractory Asthma Stratification Programme.
Lancet Respir Med
11 September 2020
Primary manuscript
Preview
Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma
Tancoš V, Grendár M, Farkašová A, Hu?ka Z, Mi?ák J, Kviatkovská Z, Hardman TC, Hardy GAD, Plank L.
Pathology
27 August 2020
Primary manuscript
Preview
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study
Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U.
Nephrol Dial Transplant
19 August 2020
Primary manuscript
Preview
Vector Copy Distribution at a Single-Cell Level Enhances Analytical Characterization of Gene-Modified Cell Therapies
Santeramo I, Bagnati M, Harvey EJ, Hassan E, Surmacz-Cordle B, Marshall D, Di Cerbo V.
Mol Ther Methods Clin Dev
19 May 2020
Review
Preview
Ten tips for promoting your research.
Hardman TC, Krentz, AJ, Wierzbicki, AS
Cardiovasc Endocrinol Metab
03 March 2020
Review
Preview
European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development-Be Prepared
Hardman T, Caplain H, Rottey S, Douglas D, Stringer S, Sourgens H.
Front Pharmacol
29 November 2019
Primary manuscript
Preview
Lumbar interbody fusion rates with 3D-printed lamellar titanium cages using a silicate-substituted calcium phosphate bone graft
Mokawem M, Katzouraki G, Harman CL, Lee R.
J Clin Neurosci
29 July 2019
Increasing the incidence of drain-free day-case mastectomies with the use of a fibrin tissue sealant; data from a single surgical center in the United Kingdom
Harrison C, Remoundos DD, Harvey KL, Stoker GV, MacLean G, Adwani A, Roy PG.
Breast J
25 July 2019
Review
Preview
The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum
Breithaupt-Grögler K, Hardman T, de Hoon J, Donazzolo Y, Rottey S, Sourgens H, Stringer S.
Front Pharmacol
24 April 2019
Primary manuscript
Preview
Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus
Rodriguez-Mañas L, Laosa O, Vellas B, Paolisso G, Topinkova E, Oliva-Moreno J, Bourdel-Marchasson I, Izquierdo M, Hood K, Zeyfang A, Gambassi G, Petrovic M, Hardman TC, Kelson MJ, Bautmans I, Abellan G, Barbieri M, Peña-Longobardo LM, Regueme SC, Calvani R, De Buyser S, Sinclair AJ; European MID-Frail Consortium.
J Cachexia Sarcopenia Muscle
23 April 2019
Primary manuscript
Preview
Evaluation of an increased strut porosity silicate-substituted calcium phosphate, SiCaPÂ EP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open-label study
Bolger C, Jones D, Czop S.
Eur Spine J
06 March 2019
Review
Preview
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development
Reijntjes S, Albayaty M, Bush J, Cheriyan J, Cromie A, Koch A, Hammond M, Mair S, Scholes P, Lorch U, Stringer S, Taubel J, Hardman TC.
Front Pharmacol
19 November 2018
Primary manuscript
Preview
A Prospective, Randomized, Multicenter Study Comparing Silicated Calcium Phosphate versus BMP-2 Synthetic Bone Graft in Posterolateral Instrumented Lumbar Fusion for Degenerative Spinal Disorders
Coughlan M, Davies M, Mostert AK, Nanda D, Willems PC, Rosenberg G, Ferch R.
Spine (Phila Pa 1976)
01 August 2018
Review
Preview
EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management
Van Bortel L, Sourgens H, Breithaupt-Grögler K, Caplain H, Donazzolo Y, Klingmann I, Hammond M, Hardman TC, Stringer S, de Hoon J.
Front Pharmacol
17 January 2018
Primary manuscript
Preview
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.
Trials
04 January 2018
Review
Preview
Ready! Aim! Fire! targeting the right medical science journal
Hardman TC, Serginson JM.
Cardiovasc Endocrinol
09 September 2017
Primary manuscript
Preview
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.
Lancet
27 May 2017
Review
Preview
Constipation in older people: A consensus statement
Emmanuel A, Mattace-Raso F, Neri MC, Petersen KU, Rey E, Rogers J.
Int J Clin Pract
09 December 2016
Primary manuscript
Preview
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W.
J Antimicrob Chemother
04 April 2016
Primary manuscript
Preview
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial
Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT.
Ann Intern Med
10 November 2015
Primary manuscript
Preview
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK.
Ann Intern Med
10 November 2015
Primary manuscript
Preview
EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study
Berlin MS, Rowe-Rendleman C, Ahmed I, Ross DT, Fujii A, Ouchi T, Quach C, Wood A, Ward CL.
Br J Ophthalmol
09 October 2015
Primary manuscript
Preview
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial
Eastell R, Dijk DJ, Small M, Greenwood A, Sharpe J, Yamada H, Yuba M, Tanimoto M, Deacon S.
Osteoporos Int
07 October 2015
Primary manuscript
Preview
Assessment of SiCaP-30 in a Rabbit Posterolateral Fusion Model with Concurrent Chemotherapy
Smucker JD, Petersen EB, Al-Hili A, Nepola JV, Fredericks DC.
Iowa Orthop J
12 September 2015
Primary manuscript
Preview
In Search of 'Omics'-Based Biomarkers to Predict Risk of Frailty and Its Consequences in Older Individuals: The FRAILOMIC Initiative
Erusalimsky JD, Grillari J, Grune T, Jansen-Duerr P, Lippi G, Sinclair AJ, Tegnér J, Viña J, Durrance-Bagale A, Miñambres R, Viegas M, RodrÃguez-Mañas L on behalf of the FRAILOMIC Consortium
Gerontology
23 July 2015
Primary manuscript
Preview
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Heaney LG, Djukanovic R, Woodcock A, Walker S, Matthews JG, Pavord ID, Bradding P, Niven R, Brightling CE, Chaudhuri R, Arron JR, Choy DF, Cowan D, Mansur A, Menzies-Gow A, Adcock I, Chung KF, Corrigan C, Coyle P, Harrison T, Johnston S, Howarth P, Lordan J, Sabroe I, Bigler J, Smith D, Catley M, May R, Pierre L, Stevenson C, Crater G, Keane F, Costello RW, Hudson V, Supple D, Hardman T.
Thorax
23 July 2015
Primary manuscript
Preview
Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects
Chen X, Zheng X, Jiang J, Hu P, Wu K, Zhuang L, Liu L, Du X, Kempsford R, Allen A.
Pharmacotherapy
11 June 2015
Review
Preview
Bariatric surgery in obese older people: Useful or not?
Reijntjes SJ, Viljoen A, Wierzbicki AS, Hardman TC
Cardiovasc Endocrinol
01 June 2015
Primary manuscript
Preview
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus
Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M.
J Viral Hepat
22 May 2015
Primary manuscript
Preview
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey
Vidall C, Fernández-Ortega P, Cortinovis D, Jahn P, Amlani B, Scotté F.
Support Care Cancer
08 May 2015
Primary manuscript
Preview
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK; PHOTON-2 study team.
Lancet
21 March 2015
Primary manuscript
Preview
Prostacyclin Synthase: Upregulation during Renal Development and in Glomerular Disease as well as Its Constitutive Expression in Cultured Human Mesangial Cells
Klein T, Klaus G, Kömhoff M
Mediators of Inflammation
18 January 2015
Primary manuscript
Preview
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks
Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C.
HIV Clin Trials
06 January 2015
Primary manuscript
Preview
Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections
Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG.
Antimicrob Agents Chemother
29 October 2014
Review
Preview
Sarcoidosis: the links between epidemiology and aetiology
Dubrey S, Shah S, Hardman T, Sharma R.
Postgrad Med J
17 September 2014
Primary manuscript
Preview
An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes--the MID-Frail study: study protocol for a randomised controlled trial
RodrÃguez-Mañas L, Bayer AJ, Kelly M, Zeyfang A, Izquierdo M, Laosa O, Hardman TC, Sinclair AJ, Moreira S, Cook J; MID-Frail Consortium.
Trials
24 January 2014
Review
Preview
New therapies to reduce low-density lipoprotein cholesterol
Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP.
Curr Opin Cardiol
06 December 2013
Primary manuscript
Preview
A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects
Liu H, Jiang J, Wang H, Chen X, Liu T, Cao H, Palmer J, Gu A, Hu P.
Clin Pharmacol Drug Dev
30 October 2013
Primary manuscript
Preview
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma
Snowise NG, Clements D, Ho SY, Follows RM.
Curr Med Res Opin
10 September 2013
Review
Preview
New therapies in the management of type 2 diabetes mellitus
Hardman TC, Dubrey SW.
Br J Hosp Med (Lond)
18 August 2013
Primary manuscript
Preview
The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study
Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, Liu C, Qu Q, Cheng Y, Li J, Cao H, Cai M, Zhu R.
Parkinsonism Relat Disord
13 August 2013
Primary manuscript
Preview
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study
Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S.
J Bone Miner Res
23 July 2013
Primary manuscript
Preview
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections
Prince WT, Ivezic-Schoenfeld Z, Lell C, Tack KJ, Novak R, Obermayr F, Talbot GH.
Antimicrob Agents Chemother
21 May 2013
Primary manuscript
Preview
Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
Follows RM, Snowise NG, Ho SY, Ambery CL, Smart K, McQuade BA.
Respir Res
17 May 2013
Primary manuscript
Preview
Eight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and women
Lopez HL, Ziegenfuss TN, Hofheins JE, Habowski SM, Arent SM, Weir JP, Ferrando AA.
J Int Soc Sports Nutr
19 April 2013
Primary manuscript
Preview
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA.
J Clin Pharmacol
07 March 2013
Primary manuscript
Preview
Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers
Suto F, Wood AT, Kobayashi M, Komaba J, Duffy K, Bruce M.
Clin Ther
07 March 2013
Primary manuscript
Preview
Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects
Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT.
Antimicrob Agents Chemother
14 February 2013
Primary manuscript
Preview
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection
Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst M, Berrey MM, Symonds WT.
Antimicrob Agents Chemother
14 February 2013
Primary manuscript
Preview
Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers
Berges A, Robertson J, Upward J, Meyers S, Chen C.
Clin Pharmacol Drug Dev
10 January 2013
Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination
Ann Allen, BA Hons1; Angela Davis, MD2; Kelly Hardes, BSc, Hons3; Lee Tombs, MSc4;and Rodger Kempsford, PhD1
Clin Ther
30 November 2012
Review
Preview
Drugs in development for the management of dyslipidaemia.
Wierzbicki AS, Hardman TC, Viljoen A
Future Prescriber
02 November 2012
Review
Preview
Cardiovascular medication in women and urinary continence.
Dubrey SW, Teoh M, Hardman TC, Vowles J
Geriatric Med
08 September 2012
Review
Preview
Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research
Hocher B, Reichetzeder C, Alter ML.
Kidney Blood Press Res
27 August 2012
Primary manuscript
Preview
Directed osteogenic differentiation of human mesenchymal stem/precursor cells on silicate substituted calcium phosphate
Cameron K, Travers P, Chander C, Buckland T, Campion C, Noble B.
J Biomed Mater Res A
26 June 2012
Primary manuscript
Preview
Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study
Emtestam L, Kaaman T, Rensfeldt K.
Mycoses
12 June 2012
Review
Preview
Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia
Wierzbicki AS, Hardman TC, Viljoen A.
Expert Opin Investig Drugs
21 May 2012
Review
Preview
Midodrine: use and current status in the treatment of hypotension.
Doyle JF, Grocott-Mason R, Hardman TC, Malik O, Dubrey SW
Br J Cardiol
03 March 2012
Review
Preview
Kerasal Nail Clinical Studies Demonstrate Early Visible Improvements in Nails Damaged by Onychomycosis
Faergemann J
Podiatary Management
01 February 2012
Review
Preview
Primary manuscript
Preview
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study
Esser S, Haberl A, Mulcahy F, Gölz J, Lazzarin A, Teofilo E, Vera J, Körber A, Staszewski S.
Eur J Med Res
10 October 2011
Primary manuscript
Preview
Early and Visible Improvements after Application of K101 in the Appearance of Nails Discoloured and Deformed by Onychomycosis.
Faergemann J, Gullstrand S, Rensfeldt K
J Cosmetics, Dermatol Sci Applications
03 September 2011
Primary manuscript
Preview
Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double-blind, randomised, placebo-controlled studies
Emtestam L, Svensson A, Rensfeldt K
Mycoses
02 September 2011
Primary manuscript
Preview
Effects of serum protein on ionic exchange between culture medium and microporous hydroxyapatite and silicate-substituted hydroxyapatite
Guth K, Campion C, Buckland T, Hing KA.
J Mater Sci Mater Med
23 August 2011
Review
Preview
Review
Preview
Establishing bioequivalence for inhaled drugs; weighing the evidence
Daley-Yates PT, Parkins DA.
Expert Opin Drug Deliv
24 June 2011
Primary manuscript
Preview
Increasing strut porosity in silicate-substituted calcium-phosphate bone graft substitutes enhances osteogenesis
Campion CR, Chander C, Buckland T, Hing K.
J Biomed Mater Res B Appl Biomater
07 March 2011
Primary manuscript
Preview
Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects
Lister N, Warrington S, Boyce M, Eriksson C, Tamaoka M, Kilborn J.
J Clin Pharmacol
07 January 2011
Review
Preview
Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'
Hardman TC, Rutherford P, Dubrey SW, Wierzbicki AS.
Curr Pharm Des
07 December 2010
Primary manuscript
Preview
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia
Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BH, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukrittayakamee S.
PLoS One
30 July 2010
Primary manuscript
Preview
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects
Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
Clin Ther
20 July 2010
Review
Preview
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH.
Liver Int
31 May 2010
Poster
Preview
Effect of Silicate-Substitution on Attachment and Early Development of Human Osteoblast-Like Cells Seeded on Microporous Hydroxyapatite Discs.
Guth K, Campion C, Buckland T, Hing KA.
ADV ENG MATERIALS
18 February 2010
Primary manuscript
Preview
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis
Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS.
Eur J Clin Pharmacol
16 September 2009
Review
Preview
Future challenges for microsomal transport protein inhibitors
Wierzbicki AS, Hardman T, Prince WT.
Curr Vasc Pharmacol
16 July 2009
Primary manuscript
Preview
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies
Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, Collins DA, Kapsi SG, Jenkins JM.
Clin Ther
19 May 2009
Primary manuscript
Preview
Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes
Rungby J.
Expert Opin Investig Drugs
12 May 2009
Primary manuscript
Preview
Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products
Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, Ortega HG.
Clin Ther
24 March 2009
Primary manuscript
Preview
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
Fuchs H, Tillement JP, Urien S, Greischel A, Roth W.
J Pharm Pharmacol
01 January 2009
Primary manuscript
Preview
Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models.
Thomas L, Tadayyon M, Mark M
J PHARMACOL EXP THERAP
28 October 2008
Primary manuscript
Preview
Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects
Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, Lorch U, Taubel J.
Br J Clin Pharmacol
11 August 2008
Review
Preview
Clinical aspects of the management of HIV lipodystrophy.
WIERZBICKI AS, PURDON SD, HARDMAN TC, KULASEGARAM R, PETERS BS
Br J Diab Vasc Dis
30 July 2008
Review
Preview
Primary manuscript
Preview
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M.
J Pharmacol Exp Ther
29 April 2008
Primary manuscript
Preview
HLA-B*5701 screening for hypersensitivity to abacavir
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team.
N Engl J Med
07 February 2008
Review
Preview
HIV lipodystrophy and its metabolic consequences: implications for clinical practice
Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS.
Curr Med Res Opin
23 January 2008
Primary manuscript
Preview
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group.
N Engl J Med
29 November 2007
Primary manuscript
Preview
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC; International Mepolizumab Study Group.
Am J Respir Crit Care Med
15 August 2007
Primary manuscript
Preview
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.
Clin Infect Dis
01 August 2007
Primary manuscript
Preview
Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor
Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB.
J Pharmacol Exp Ther
26 March 2007
Primary manuscript
Preview
Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone
Allen-Ramey FC, Markson LE, Riedel AA, Sajjan S, Weiss KB.
Curr Med Res Opin
28 July 2006
Review
Preview
Characterization of the metabolites of alosetron in experimental animals and human
Ismail IM, Andrew PD, Cholerton J, Roberts AD, Dear GJ, Taylor S, Koch KM, Saynor DA.
Xenobiotica
16 July 2006
Primary manuscript
Preview
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison
Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ.
Lancet
27 June 2006
Primary manuscript
Preview
Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years
McEwan P, Baboolal K, Dixon S, Conway P, Currie CJ.
Curr Med Res Opin
26 November 2005
Primary manuscript
Preview
Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus
Cockcroft JR, Wilkinson IB, Evans M, McEwan P, Peters JR, Davies S, Scanlon MF, Currie CJ.
Am J Hypertens
11 November 2005
Primary manuscript
Preview
A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers
Hindmarch I, Trick L, Ridout F.
Psychopharmacology (Berl)
05 October 2005
Primary manuscript
Preview
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L; QUEST Study Group.
J Infect Dis
15 August 2005
Primary manuscript
Preview
A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo
Hindmarch I, Dawson J, Stanley N.
Sleep
01 February 2005
Primary manuscript
Preview
Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects
Kempsford R, Handel M, Mehta R, De Silva M, Daley-Yates P.
Respir Med
22 January 2005
Primary manuscript
Preview
The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications
Currie CJ, Morgan CL, Dixon S, McEwan P, Marchant N, Bearne A, Sharplin P, Peters JR.
Diabetes Res Clin Pract
22 December 2004
Primary manuscript
Preview
Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death
Currie CJ, Morgan CL, Dixon S, McEwan P, Marchant N, Bearne A, Sharplin P, Peters JR.
Diabetes Res Clin Pract
19 August 2004
Primary manuscript
Preview
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients
Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ.
Clin Infect Dis
15 August 2004
Primary manuscript
Preview
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.
AIDS
23 July 2004
Primary manuscript
Preview
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)
Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.
Curr Med Res Opin
22 July 2004
Primary manuscript
Preview
Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study
Anderson D, Kato N, Onomichi K, Uchida H, Shelley S, Engert D, Ilgenfritz J.
Int J Clin Pharmacol Ther
08 June 2004
Review
Preview
Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate
Evans M, McEwan P, Peters JR, Currie CJ.
Diabetes Obes Metab
26 May 2004
Primary manuscript
Preview
Brief but efficient: acute HIV infection and the sexual transmission of HIV
Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, Goh LE, Cohen MS; Quest Study; Duke-UNC-Emory Acute HIV Consortium.
J Infect Dis
15 May 2004
Primary manuscript
Preview
Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service
Currie CJ, Patel TC, McEwan P, Dixon S.
Transfus Med
25 March 2004
Primary manuscript
Preview
GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks
MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W.
AIDS
05 March 2004
Primary manuscript
Preview
Evaluating the performance of the Framingham risk equations in a population with diabetes
McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, Currie CJ.
Diabet Med
20 February 2004
Primary manuscript
Preview
A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
Barnett AH, Anderson DM, Shelley S, Morgan R, Owens DR.
Diabetes Obes Metab
26 January 2004
Primary manuscript
Preview
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients
Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG.
J Acquir Immune Defic Syndr
07 January 2004
Primary manuscript
Preview
Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease
Singh SD, Whale C, Houghton N, Daley-Yates P, Kirby SM, Woodcock AA.
Br J Clin Pharmacol
12 April 2003
Primary manuscript
Preview
The effect of nateglinide taken with food on gastric emptying rates in healthy subjects
Anderson D, Shelley S, Kellett N, Marshall D, Nimmo W.
Clin Ther
03 March 2003
Primary manuscript
Preview
No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers
Anderson DM, Shelley S, Crick N, Buraglio M.
J Clin Pharmacol
05 December 2002
Review
Preview
The cardiological complications associated with HIV infection and acquired immune deficiency syndrome (AIDS).
Hardman TC, Purdon SD
Br J Cardiol
12 November 2002
Primary manuscript
Preview
A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers
Anderson DM, Shelley S, Crick N, Buraglio M.
Int J Clin Pharmacol Ther
25 October 2002
Primary manuscript
Preview
Correction for the adverse influence of sodium-potassium cotransport on apparent sodium-lithium countertransport activity in human erythrocytes
Hardman TC, Morrish Z, Patel M, Chalkley S, Noble MI.
J Pharmacol Toxicol Methods
04 October 2002
Case History
Preview
A patient with HIV-1 superinfection
Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, Autran B, Goh LE, Perrin L.
N Engl J Med
06 September 2002
Primary manuscript
Preview
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers
Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT.
J Clin Pharmacol
07 August 2002
Primary manuscript
Preview
The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter
Wierzbicki AS, Hardman TC, Cheung J, Lambert-Hammill M, Patel S, Morrish Z, Lumb PJ, Lant AF.
Am J Hypertens
01 July 2002
Primary manuscript
Preview
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection
Andersson J, Kinloch S, Sönnerborg A, Nilsson J, Fehniger TE, Spetz AL, Behbahani H, Goh LE, McDade H, Gazzard B, Stellbrink H, Cooper D, Perrin L.
J Infect Dis
01 May 2002
Primary manuscript
Preview
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection
Loré K, Sönnerborg A, Broström C, Goh LE, Perrin L, McDade H, Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, van Kooyk Y, Andersson J.
AIDS
20 April 2002
Primary manuscript
Preview
HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial
Jabs DA, Gilpin AM, Min YI, Erice A, Kempen JH, Quinn TC; Studies of Ocular Complications of AIDS Research Group.
AIDS
29 March 2002
Primary manuscript
Preview
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection
Tilling R, Kinloch S, Goh LE, Cooper D, Perrin L, Lampe F, Zaunders J, Hoen B, Tsoukas C, Andersson J, Janossy G; Quest Study Group.
AIDS
08 March 2002
Letter
Preview
Sodium-lithium countertransport activity is linked to chromosome 5 in baboons
Hardman TC, Noble MI.
Hypertension
01 December 2001
Letter
Preview
Apolipoprotein E gene polymorphism and sodium-lithium countertransport activity
Hardman T, Noble MIM
Metabolism
22 November 2001
Primary manuscript
Preview
Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study
Goh LE, Perrin L, Hoen B, Cooper D, Phillips A, Janossy G, Sonnenborg A, Tsoukas C, Lampe F, Kinloch S; QUEST Study Group.
HIV Clin Trials
24 October 2001
Primary manuscript
Preview
Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects
Luzio SD, Anderson DM, Owens DR.
J Clin Endocrinol Metab
16 October 2001
Primary manuscript
Preview
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers
Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.
J Clin Pharmacol
05 October 2001
Letter
Preview
Erythrocyte sodium-lithium countertransport in African American women
Hardman TC, Wierzbicki AS.
J Hum Hypertens
18 July 2001
Primary manuscript
Preview
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers
Cass LM, Moore KH, Dallow NS, Jones AE, Sisson JR, Prince WT.
J Clin Pharmacol
22 May 2001
Review
Preview
The current status of antihypertensive treatments: into the new millennium
Hardman TC, Lunnon MW.
Expert Opin Pharmacother
05 May 2001
Primary manuscript
Preview
Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor
Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.
Eur J Clin Pharmacol
11 April 2001
Primary manuscript
Preview
Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia
Wierzbicki AS, Hardman TC, Cheung J, Patel M, Smallberger S, Lumb PJ, Lant AF.
Am J Hypertens
24 February 2001
Changes in referral patterns to cardiac out-patient clinics with ambulatory ECG monitoring in general practice.
Standing P, Dent M, Craig A, Glenville B
Br J Cardiol
22 January 2001
Primary manuscript
Preview
Brain and CSF entry of the novel non-nucleoside reverse transcriptase inhibitor, GW420867X
Thomas S, Cass L, Prince W, Segal M.
Neuroreport
27 November 2000
Review
Preview
Review
Preview
The QUEST trial, a paradigm of HIV collaborative research
Goh LE, McDade H, Kinloch S, Perrin L, Cooper D, Phillips A, Hoen B, Autran B, Sonnerborg A, Tsoukas C.
Nat Med
04 November 2000
Primary manuscript
Preview
Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter
Wierzbicki AS, Hardman TC, Cheung J, Lambert-Hammill M, Patel S, Morrish Z, Lumb PJ, Lant AF.
J Hum Hypertens
06 September 2000
Primary manuscript
Preview
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
Mallal SA, John M, Moore CB, James IR, McKinnon EJ.
AIDS
07 July 2000
Primary manuscript
Preview
Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects
Hardman TC, Dubrey SW, Soni S, Clifford R, Chalkley S, Wierzbicki AS.
J Hum Hypertens
05 January 2000
Review
Preview
Natriuretic peptides and heart failure: diagnosis, prognosis and treatment.
Dubrey SW, Hardman TC
Br J Cardiol
01 January 2000
Letter
Preview
Erythrocyte Na+/Li+ countertransport and Na+/K+ -2Cl- co-transport in essential hypertension
Hardman T, Clifford RH, Wierzbicki AS.
Clin Sci (Lond)
30 November 1999
Letter
Preview
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X
Hardman TC, Clifford RH, Dubrey SW.
J Am Coll Cardiol
14 September 1999
Primary manuscript
Preview
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee
Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M.
J Infect Dis
07 August 1999
Letter
Preview
Primary manuscript
Preview
Transport of phytanic acid on lipoproteins in Refsum disease
Wierzbicki AS, Sankaralingam A, Lumb PJ, Hardman TC, Sidey MC, Gibberd FB.
J Inherit Metab Dis
10 March 1999
Urine pterin levels in patients with pre-cancerous lesions of the uterine cervix.
Rippin J
01 February 1999
Letter
Preview
Relationship of Mean Cell Volume and Blood Lead in London Schoolchildren at Low Lead Levels.
Chalkley S
01 August 1998
Erythrocyte sodium lithium countertransport (SLC) activity and retinol binding protein (RBP) in healthy normotensive subjects.
Hardman TC
Clin Sci (Lond)
01 August 1998
Effects of exposure to lead and cadmium on metabolism of vitamin D3 in smelter workers.
Chalkley S
01 July 1998
Primary manuscript
Preview
Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter
Wierzbicki AS, Hardman TC, Lumb P, Sankaralingam A, Morrish Z, Patel F, Sidey MC, Gibberd FB.
Eur J Clin Invest
06 June 1998
Primary manuscript
Preview
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in black normotensive subjects compared with three other ethnic groups
Hardman TC, Croft P, Morrish Z, Anto-Awoakye K, Lant AF.
J Hum Hypertens
03 March 1998
Iron deficiency in a cohort of school children living within the inner-city London area.
Chalkley S
01 February 1998
Primary manuscript
Preview
Characterization of the erythrocyte sodium-lithium countertransporter: limitations and assumptions of traditional and kinetic methodologies
Hardman TC, Thomas T, Lant AF.
J Membr Biol
22 January 1998
Letter
Preview
Primary manuscript
Preview
Kinetic behavior of the erythrocyte sodium-lithium countertransporter in nonnephropathic diabetic twins
Hardman TC, Dubrey SW, Leslie RD, Lant AF.
Metabolism
01 October 1996
Review
Preview
Controversies surrounding erythrocyte sodium-lithium countertransport
Hardman TC, Lant AF.
J Hypertens
01 June 1996
Primary manuscript
Preview
Angiotensin-converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in hypertension
Hardman TC, Wierzbicki AS, Croft P, Feher M, Cox A, Lant AF.
J Hum Hypertens
01 June 1996
Primary manuscript
Preview
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery disease
Hardman TC, Barlow R, Dubrey SW, Croft P, Lant AF.
Am J Hypertens
01 February 1996
Primary manuscript
Preview
Erythrocyte sodium-lithium countertransport activity in non-nephropathic diabetic twins
Hardman TC, Dubrey SW, Leslie RD, Lant AF.
Diabetes Care
01 January 1996
Primary manuscript
Preview
Ethnic origin and hypertension-associated alterations in sodium-lithium countertransport kinetics
Hardman TC, Croft P, Barlow R, Wierzbicki AS, Feher MD, Lant AF.
J Hum Hypertens
01 August 1995
Primary manuscript
Preview
Relation of sodium-lithium countertransport activity to markers of cardiovascular risk in normotensive subjects
Hardman TC, Dubrey SW, Soni S, Lant AF.
J Hum Hypertens
01 July 1995
Review
Preview
Primary manuscript
Preview
Lack of acute effects of a standardised fat meal or exercise on erythrocyte sodium-lithium countertransport activity
Hardman TC, Dubrey SW, Barlow R, Feher MD, Lant AF.
J Hum Hypertens
01 August 1994
Triglyceride not insulin resistance principally determines sodium-lithium countertransport activity in patients with hyperchylomicronaemia
Wierzbicki AS
Am J Hypertens
01 April 1994
Primary manuscript
Preview
Exercise electrocardiography and aortic Doppler velocimetry in asymptomatic identical twins discordant for type 1 (insulin dependent) diabetes.
Dubrey S, Akhras F, Song GJ, Hardman T, Travill C, Hynd J, Noble MI, Lo SS, Leslie RD.
Br Heart J
01 April 1994
Primary manuscript
Preview
Erythrocyte sodium-lithium countertransport and blood pressure in identical twin pairs discordant for insulin dependent diabetes
Hardman TC, Dubrey SW, Leslie DG, Hafiz M, Noble MI, Lant AF.
BMJ
25 July 1992
